Trial
NCT03016091
A Trial of Pembrolizumab for Refractory Atypical and Anaplastic Meningioma
Phase IITERMINATEDSAFETYConfidence: MEDIUM
Sponsor
Rabin Medical Center
Collaborators
—
Condition
Atypical Meningioma
Intervention
Pembrolizumab
Why stopped
Slow accrural, dismal results
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-02-18